Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab with TACE in HCC
NCT02997956Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in hepatocellular carcinoma (HCC), sponsored by University of Michigan Rogel Cancer Center. Planned start Jul 2017; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02997956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997956.